Sector News

India’s Dr Reddy’s to buy some UCB brands for $128 mln

April 2, 2015
Life sciences
(Reuters) – India’s second-largest drugmaker by sales, Dr Reddy’s Laboratories Ltd, will buy some established brands of Belgian drugmaker UCB SA in South Asia for 8 billion rupees ($128.38 million), the company said on Wednesday.
 
As competition heats up, Indian drugmakers are looking to strengthen existing porfolios in fast-growing emerging markets, as well as at home.
 
The country’s largest drugmaker, Sun Pharmaceutical Industries Ltd, closed a deal to buy rival Ranbaxy Laboratories Ltd last month, strengthening its presence, particularly in emerging markets.
 
Dr Reddy’s said the acquisition of brands in India, Nepal, Sri Lanka and the Maldives, would help it win a bigger foothold in the areas of respiratory, dermatology and pediatrics drugs.
 
The acquired business generated revenue of about 1.5 billion rupees in 2014, Dr Reddy’s said.
 
The India part of the business employs about 350 people.
 
Some brokerege analysts, however, expressed concern about the acquisition cost, with the deal valuing the UCB business more than five times its sales, which, they said, was higher than the industry standard.
 
“You would demand this kind of valuation when you’re buying the leader in the industry. And I’m not sure if Dr Reddy’s has got leading brands from UCB,” said Nimish Mehta of Equirus Securities.
 
UCB Chief Operating Officer Mark McDade said in a statement the deal would allow the Belgian company to sharpen its focus on its neurology portfolio in India. Dr Reddy’s said it expected to close the deal in the first quarter of this financial year.
 
Last month, Reuters reported that Dr Reddy’s was in talks with UCB for a deal concerning the latter’s Indian operations, citing a source with direct knowledge of the matter. ($1=62.3150 Indian rupees) (Reporting by Zeba Siddiqui in Mumbai; Editing by Clarence Fernandez; Editing by Sumeet Chatterjee and Clarence Fernandez)

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach